John J. Greer of U. Alberta demonstrated that one AMPAKINE compounds enhance the respiratory travel and breathing rhythm at the brain-stem level containing the pre-Botzinger Complex in laboratory rats whose respiration rates were purposely suppressed by administration of central nervous system depressants. Dr. Greer discovered that respiratory depression induced by these agents can be reversed or prevented in test pets with an experimental AMPAKINE drug, without a reduced amount of pain sedation or relief. Coworkers and Greer treated rats with the opioids analgesic fentanyl or the barbiturate sedative Phenobarbital, both prescribed in the United States commonly. Greer used a technique known as plethysmography, which measures blood flow through the entire physical body, to determine the level of respiratory distressed caused by the drugs.Efficacy Venograms that may be evaluated were obtained in 281 of the 293 patients who have received study medication . Seven of the patients whose venograms could be evaluated underwent venography outside the 8-to-12-day postoperative period, and only 1 1 had deep-vein thrombosis. These 7 sufferers had been excluded from the per-protocol population. There have been no other major protocol violations. In the per-protocol human population, the principal efficacy outcome occurred in 36 of 134 patients in the 200-mg FXI-ASO group, in 3 of 71 patients in the 300-mg FXI-ASO group, and in 21 of 69 patients in the enoxaparin group. The modified intention-to-treat analysis yielded very similar results . Both FXI-ASO regimens met the prespecified criteria for noninferiority, and the 300-mg FXI-ASO regimen was more advanced than enoxaparin .